Black Diamond Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BDTX and other ETFs, options, and stocks.About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases.
CEOMark A. Velleca
CEOMark A. Velleca
Employees24
Employees24
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees24
Employees24
BDTX Key Statistics
Market cap150.98M
Market cap150.98M
Price-Earnings ratio7.69
Price-Earnings ratio7.69
Dividend yield—
Dividend yield—
Average volume2.35M
Average volume2.35M
High today$2.82
High today$2.82
Low today$2.64
Low today$2.64
Open price$2.82
Open price$2.82
Volume887.25K
Volume887.25K
52 Week high$4.94
52 Week high$4.94
52 Week low$1.20
52 Week low$1.20
Stock Snapshot
The current Black Diamond Therapeutics(BDTX) stock price is $2.65, with a market capitalization of 150.98M. The stock trades at a price-to-earnings (P/E) ratio of 7.69.
On 2025-12-16, Black Diamond Therapeutics(BDTX) stock moved within a range of $2.64 to $2.82. With shares now at $2.65, the stock is trading +0.3% above its intraday low and -6.0% below the session's peak.
Trading volume for Black Diamond Therapeutics(BDTX) stock has reached 887.25K, versus its average volume of 2.35M.
Over the past 52 weeks, Black Diamond Therapeutics(BDTX) stock has traded between a high of $4.94 and a low of $1.20.
Over the past 52 weeks, Black Diamond Therapeutics(BDTX) stock has traded between a high of $4.94 and a low of $1.20.
Analyst ratings
89%
of 9 ratingsBuy
88.9%
Hold
11.1%
Sell
0%
People also own
Based on the portfolios of people who own BDTX. This list is generated using Robinhood data, and it’s not a recommendation.